Andy Rittenberg - Coherus BioSciences Executive Counsel

Coherus BioSciences Management Efficiency

The company has return on total asset (ROA) of (0.1094) % which means that it has lost $0.1094 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.5706) %, meaning that it created substantial loss on money invested by shareholders. Coherus BioSciences' management efficiency ratios could be used to measure how well Coherus BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Coherus BioSciences' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.07 in 2025, whereas Return On Capital Employed is likely to drop (0.71) in 2025. At this time, Coherus BioSciences' Other Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 35.9 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 56.5 M in 2025.

Similar Executives

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 368 people. Coherus BioSciences (CHRS) is traded on NASDAQ Exchange in USA. It is located in 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 and employs 228 people. Coherus BioSciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Coherus BioSciences Leadership Team

Coherus Stock Performance Indicators

Additional Tools for Coherus Stock Analysis